Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.

ABSTRACT:

Purpose

The prognosis of patients with multiple myeloma who are resistant to proteasome inhibitors, immunomodulatory drugs (IMiD), and daratumumab is extremely poor. Even B-cell maturation antigen-specific chimeric antigen receptor T-cell therapies provide only a temporary benefit before patients succumb to their disease. In this article, we interrogate the unique sensitivity of multiple myeloma cells to the alternative strategy of blocking protein translation with omacetaxine.

Experimental design

We determined protein translation levels (n = 17) and sensitivity to omacetaxine (n = 51) of primary multiple myeloma patient samples. Synergy was evaluated between omacetaxine and IMiDs in vitro, ex vivo, and in vivo. Underlying mechanism was investigat

SUBMITTER: Walker ZJ 

PROVIDER: S-EPMC7854501 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature